Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
243.01
-9.26 (-3.67%)
Aug 1, 2025, 4:00 PM - Market closed
Penumbra Revenue
Penumbra had revenue of $339.46M in the quarter ending June 30, 2025, with 13.38% growth. This brings the company's revenue in the last twelve months to $1.28B, up 12.92% year-over-year. In the year 2024, Penumbra had annual revenue of $1.19B with 12.86% growth.
Revenue (ttm)
$1.28B
Revenue Growth
+12.92%
P/S Ratio
7.33
Revenue / Employee
$284,478
Employees
4,500
Market Cap
9.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PEN News
- 2 days ago - Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference - PRNewsWire
- 3 days ago - Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Penumbra, Inc. Reports Second Quarter 2025 Financial Results - PRNewsWire
- 10 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 4 weeks ago - Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 - PRNewsWire
- 5 weeks ago - Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner - Seeking Alpha
- 6 weeks ago - Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial - PRNewsWire
- 2 months ago - Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization - PRNewsWire